Carregant...
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs()
Histone deacetylases (HDACs) are validated drug targets for cancer treatment. Increased HDAC isozyme selectivity and novel strategies to inhibit HDAC activity could lead to safer and more effective drug candidates. Nonetheless, it is quite challenging to develop isozyme-specific HDACi due to the hig...
Guardat en:
| Publicat a: | Chem Commun (Camb) |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7654701/ https://ncbi.nlm.nih.gov/pubmed/32840532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/d0cc03243c |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|